Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Diabetes, Genomics, Memory, Obesity, Parkinson's Disease
MD, University of Milan Medical School
PhD, University of Milan
Foundation Queen Sofia of Spain Research Center award on Alzheimer's Disease
Temple Foundation Discovery Award from Alzheimer's Association
Nathan Shock New Investigator Award of the Gerontology Society of America
Faculty Council Award for Academic Excellence
Mount Sinai School of Medicine
Nathan W. & Margaret T. Shock Aging Research Foundation Award of the Gerontology Society of America
Turken Family fellowship from Alzheimer's Association
Los Angeles Chapter
Dana Alliance for Brain Initiatives Award
Zenith Award from Alzheimer's Association
Look AHEAD (Action for Health in Diabetes)
Dr. Pasinetti's laboratory is currently focused on building a model based on genetic and environmental information to predict cognitive decline in overweight and obese individuals with type 2 diabetes. Ultimately, the study will allow the prediction of the long-term effects of intensive weight loss intervention in the Look AHEAD (Action for Health in Diabetes) study. The lab will use independent study cohorts from other Biobanks to validate their comprehensive model. These studies will be critical for developing and redirecting efforts for potential therapeutic intervention in a subpopulation of type 2 diabetic subjects who are at high risk for cognitive deterioration.
The primary research goals of Dr. Pasinetti's lab is to investigate the biological processes which occur when, during aging, subjects with normal cognitive function convert into the very earliest stages of Alzheimer's disease and then to frank dementia. More recently, Dr. Pasinetti has conducted genome wide association studies to clarify the molecular mechanisms in subjects with type 2 diabetes that might be predisposed to the onset of Alzheimer’s disease.
As Director of the NIH funded Botanical Center in Neuroresilience, Dr Pasinetti is investigating certain dietary supplements, in particular polyphenols, against stressful events and clarifying the role of the microbiome at the genomic level in the promotion of cognitive and psychological health. Dr. Pasinetti received a competitive award for $10 million for five years to conduct research under his leadership in the Department of Neurology. The Center will support three major projects which will be conducted through interdisciplinary collaborative efforts from the Department of Neuroscience, Department of Neurology, Department of Genetics and Genomic Sciences, and the Friedman Brain Institute. The Center research will lead to safe and efficacious treatments of dietary botanical supplements to promote resilience in response to psychological and cognitive stress.
Drug discovery and repurposing
As Chief of the Brain Institute Center of Excellence for Novel Approaches to Neurodiagnostics and Neurotherapeutics, Dr. Pasinetti has developed novel drug discovery programs for Alzheimer’s disease. Dr. Pasinetti is leading a primary translational Center to determine whether interventions which appear to work in the preclinical animal model of the disease also show promise in treating patients who have the disease. Dr. Pasinetti is utilizing innovative, drug discovery, genomic and proteomic technologies, which offer the promise to shed light on largely unseen details of disease causality, onset, and progression. Through the approach of “repurposing currently used drugs for other indications” Dr. Pasinetti is currently identifying new therapies that will provide clinical benefits
Dr. Pasinetti is the Director of Basic and Biomedical Research and Training at the Geriatric Education and Clinical Research at the James J Peters Veterans Affairs, Bronx where he developed programs to train health science students in the field of geriatrics in order to help increase the basic knowledge of aging, transmit this knowledge to health care providers, and improve the quality of care delivered to elders. Collectively, the work of Dr. Pasinetti directly develops research to improve the care and treatment for the aging Veteran population while at the same time training many of the healthcare professionals who will provide that care for years to come.
Pasinetti GM. Towards prevention and therapy of Alzheimer's disease. Molecular Aspects of Medicine; 43-44.
Hao K, Di Narzo AF, Ho L, Luo W, Li S, Chen R, Li T, Dubner L, Pasinetti GM. Shared genetic etiology underlying Alzheimer's disease and type 2 diabetes. Molecular Aspects of Medicine 2015 Jun;.
Wang D, Ho L, Faith J, Ono K, Janle EM, Lachcik PJ, Cooper BR, Jannasch AH, D'Arcy BR, Williams BA, Ferruzzi MG, Levine S, Zhao W, Dubner L, Pasinetti GM. Role of intestinal microbiota in the generation of polyphenol-derived phenolic acid mediated attenuation of Alzheimer's disease β-amyloid oligomerization. Molecular nutrition & food research 2015 Jun; 59(6).
Vidaurre OG, Haines JD, Katz Sand I, Adula KP, Huynh JL, McGraw CA, Zhang F, Varghese M, Sotirchos E, Bhargava P, Bandaru VV, Pasinetti G, Zhang W, Inglese M, Calabresi PA, Wu G, Miller AE, Haughey NJ, Lublin FD, Casaccia P. Cerebrospinal fluid ceramides from patients with multiple sclerosis impair neuronal bioenergetics. Brain 2014 Aug; 137(Pt 8).
Wang J, Bi W, Cheng A, Freire D, Vempati P, Zhao W, Gong B, Janle EM, Chen TY, Ferruzzi MG, Schmeidler J, Ho L, Pasinetti GM. Targeting multiple pathogenic mechanisms with polyphenols for the treatment of Alzheimer's disease-experimental approach and therapeutic implications. Frontiers in aging neuroscience 2014; 6.
Wang J, Gong B, Zhao W, Tang C, Varghese M, Nguyen T, Bi W, Bilski A, Begum S, Vempati P, Knable L, Ho L, Pasinetti GM. Epigenetic mechanisms linking diabetes and synaptic impairments. Diabetes 2014 Feb; 63(2).
Wang J, Ferruzzi MG, Ho L, Blount J, Janle E, Gong B, Pan Y, Raftery D, Arrieta-Cruz I, Sharma V, Cooper B, Lobo J, Simon JE, Zhang C, Cheng A, Qian X, Ono K, Teplow D, Pavlides C, Dixon R, Pasinetti GM. Brain Targeting Proanthocyanidin Metabolites for Alzheimer’s Disease Treatment . Journal of Neuroscience 2012;.
Dixon RA, Pasinetti GM. Flavonoids and isoflavonoids: from plant biology to agriculture and neuroscience. Plant physiology 2010 Oct; 154(2).
Qin W, Haroutunian V, Katsel P, Cardozo CP, Ho L, Buxbaum JD, Pasinetti GM. PGC-1alpha expression decreases in the Alzheimer disease brain as a function of dementia. JAMA Neurology 2009 Mar; 66(3).
Pasinetti GM. Anti-inflammator drugs fall short in Alzheimer's disease. Nature Medicine 2008; 14(9).
Wang J, Ho L, Zhao W, Ono K, Rosensweig C, Chen L, Humala N, Teplow DB, Pasinetti GM. Grape-derived polyphenolics prevent Abeta oligomerization and attenuate cognitive deterioration in a mouse model of Alzheimer's disease. The Journal of Neuroscience 2008 Jun; 28(25).
Pasinetti GM, Ungar LH, Lange DJ, Yemul S, Deng H, Yuan X, Brown RH, Cudkowicz ME, Newhall K, Peskind E, Marcus S, Ho L. Identification of potential CSF biomarkers in ALS. Neurology 2006 Apr; 66(8).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Pasinetti did not report having any of the following types of financial relationships with industry during 2016 and/or 2017: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.